Home › Companies › PCSA

Processa Pharmaceuticals

Market cap $4.8M 2.8M shares (10-Q, Nov 9, 2026) × $1.73 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. VT-7208 corporate update2H 2026VT-7208 corporate update, 2H 2026, routine
  2. Preferred Stock Conversion Proposal corporate4Q 2026Preferred Stock Conversion Proposal corporate, 4Q 2026, routine
  3. Series A Preferred corporate update1Q 2027Series A Preferred corporate update, 1Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Technology platforms

FcRn antagonist program · Generian Pharmaceuticals

Preclinical oral neonatal Fc receptor (FcRn) antagonist being explored for treatment of immune-mediated diseases, advanced under a research collaboration and exclusive option agreement with Generian Pharmaceuticals

Targets: FcRn

Discontinued (1)

Capital (as filed)

Cash
$180M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$5.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$180M cash, runway H2 2029 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Processa Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Avoid Processa Pharmaceuticals (PCSA) - Scientific Deep Dive for PCS6422 and Pipeline Products Interesting DPD-inhibition pharmacology is overwhelmed by an existential IP termination lawsuit over the lead asset, a going-concern cash crisis, and management diverting clinical runway into cryptocurrency speculation.
  2. Avoid UPDATE: Processa Pharmaceuticals (PCSA) - The Cash Crash and the Crypto Doubling-Down Q1 10-Q confirms every red flag: cash collapsed from $5.5M to $1.7M in one quarter, the company bought more CHZ crypto, the Elion IP suit grinds on, and outside institutional appetite is effectively zero.
  3. Speculative buy speculative UPDATE: Processa Pharmaceuticals (PCSA) - The Shell Gets a Real Drug A reverse merger with Vidya Therapeutics and a $200M PIPE from Bain/RA Capital/Cormorant transforms the shell into a funded, Phase 1-complete CNS-penetrant BTK inhibitor company with three parallel Phase 2 shots, though legacy holders are diluted to ~0.9% and the PIPE price of $1.22 is the key entry anchor.
  4. Speculative buy speculative UPDATE: Processa Pharmaceuticals (PCSA) - The Adults Take the Wheel FDA cleared the CSU Phase 2 IND on schedule and Sheila Gujrathi was promoted to Executive Chair over capital allocation, addressing the stewardship concern flagged in July, while the PIPE anchor of $1.22 remains the key entry reference.
  5. Speculative buy speculative UPDATE: Processa Pharmaceuticals (PCSA) - The Vote Slips, the Clock Starts The preferred-conversion vote slipped to Q1 2027 against a late-April cash-settlement deadline, Gossamer milestones up to $165.5M were disclosed, and the CHZ crypto position is being unwound at a loss, but the $180M funded balance sheet and BTK thesis remain intact.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (21)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 29, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)